Jamie Manuell Year 2 Pharmacology & Therapeutics.

239
Jamie Jamie Manuell Manuell Year 2 Year 2 Pharmacolog Pharmacolog y & y & Therapeutic Therapeutic s s

Transcript of Jamie Manuell Year 2 Pharmacology & Therapeutics.

Page 1: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Jamie Jamie ManuellManuell

Year 2Year 2

PharmacologPharmacology & y &

TherapeuticsTherapeutics

Page 2: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs and the Autonomic Nervous System

Page 3: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Cholinomimetics

Directly Acting

Page 4: Jamie Manuell Year 2 Pharmacology & Therapeutics.

acetylcholine

Class Directly acting cholinomimetic

MOA Neurotransmitter. Acts on muscarinic or nicotinic receptors. in Autonomic NS

Indications

Side Effects

Other

Page 5: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Bethanecol

Class Directly acting cholinomimeticParasympathomimetic

MOA Choline ester, selective for muscarinic receptors, then M3. Not acted on by acetylcholinesterase so long lasting. They increase detrussor muscle contraction, by stimulating post synaptic receptors

Indications Gut and Bladder stimulation postoperatively

Side effects Bronchoconstriction / secretion, salivation

Other

Page 6: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Pilocarpine

Class Directly acting cholinomimetics, i.e. muscarinic agonist

MOA Alkaloid, selective for muscarinic receptors. Causes constriction of the constrictor pupillae muscles of the iris, allowing aqueous humour to drain into trabecular meshwork.

Indications Given to treat glaucoma (by causing pupil constriction and therefore aiding drainage)

Side Effects Eye irritation, headache and browache, blurred vision, hypersalivation, may exacerbate asthma.

Other Not with acute iritis, anterior uvetis

Page 7: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Cholinomimetics

Indirectly Acting

Page 8: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Neostigmine

Class Intermediate lasting Anticholinesterase

MOA Inhibits acetylcholinesterase by addition of a Carbamyl group to the enzyme and so increases the amount of ACh in the synaptic cleft.

Indications Used IV to reverse the effects of non depolarising blockers. Shows some selectivity for the NMJ

Side Effects

Other Despite selectivity, atropine is sometimes co-administered to block muscarinic effects of the drug.

Page 9: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Physostigmine

Class Intermediate acting anticholinesterase.

MOA Inhibit AChE so increasing amount of ACh in the synaptic cleft. Shows selectivity for the postganglionic parasympathetic junction.

Indications Used to constrict the pupil, and contract the ciliary muscle in glaucoma.

Side Effects Initial excitation, followed by depression, followed by respiratory depression and unconsciousness.

Other Tertiary amine, so can cross the blood/brain barrier. Central effects can be combated by atropine.

Page 10: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Ecothiapate

Class Long lasting anticholinesterase. Organophosphorous compound.

MOA Irreversible inhibitor of AChE, so increasing ACh duration of action in synaptic cleft. Inhibit enzyme by phosphorylation. Enhance muscarinic activity. Moderate dose affects all autonomic ganglia, high doses causes depolarising block at ganglia.

Indications Treatment of glaucoma

Side Effects Bradycardia, breathing problems, depolarizing neuromuscular block, central effects, and possible death form peripheral nerve demyelination.

Other Phosphorylated enzyme is stable, so new enzymes have to be produced to regain function.

Page 11: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Cholinoceptor Antagonists

Muscarinic Antagonists

Page 12: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Atropine

Class Non selective Muscarinic cholinoceptor Antagonist

MOA Bind to receptor, but has no intrinsic activity, effect therefor depends on previous level of supplied tone by the agonist.

Indications Reduces gastrointestinal motility, cardiac arrest, prevent salivation, bronchial secretions, protect heart from arrhythmias, particularly those caused by neuromuscular blockers.

Side Effects Dry mouth and skin, raised body temperature, dilatation of pupil, relaxation of ciliary msucle (no accomodation) urinary retention, irritability and hyperactivity

Other Different tissues have different levels of responsiveness. Salivary, sweat, bronchial>parietal cells production of gastric acid. Treat poisoning with anticholinesterase drugsThe one from the belladonna alkaloids, found in deadly nightshade.

Page 13: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Class Muscarinic Receptor Antagonist, antiemetic

MOA Binds to receptor making it inaccessible for ACh to activate receptor. Emetic actions in vest. Nuclei, NTS, vomiting centre, to block VC’s activation.

Indications Used to prevent bronchial secretions and salivations.protect heart from arrhythmias, particularly those caused by neuromuscular blockers. Prevention of motion sickness, parkinson’s disease.

Side Effects Dry mouth and skin, raised body temperature, dilatation of pupil, relaxation of ciliary msucle (no accomodation) urinary retention, irritability and hyperactivity. Drowsiness, slow gut movement.

Other Different tissues have different levels of responsiveness. Salivary, sweat, bronchial>parietal cells production of gastric acid.

Hyoscine(Scopoloamine)

Page 14: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Tropicamide

Class Non-selective Muscarinic cholinoceptor Antagonist

MOA

Indications Motion sickness, to dilate the pupil to view the retina.

Side Effects Low exocrine secretions, initial drop in HR followed by tachycardia. Initial excitation, then depression, amnesia, tranquility, OD – Coma, respiratory depression, death

Other

Page 15: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Ipratropium Bromide

Class Muscarinic Receptor Antagonist, parasympatholytic

MOA Inhaled, blocks action of acetylcholine.

Indications Used in bronchodilation. For asthma and obstructive airways disease.

Side Effects Systemic effects of blocking muscarinic cholinoceptors.

Other

Page 16: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Cholinoceptor Antagonists

Nicotinic Antagonists

Page 17: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Trimetapham

Class Short lasting Nicotinic cholinoceptor Antagonist (also known as ganglion blockade)

MOA Blocks transmission at all autonomic ganglia (parasympathetic and sympathetic).

Indications Used clinically to provide 2-3 minutes of hypotension in surgery

Side Effects Drop BP, Impaired postural reflexes, reduced renin secretion, decreased GI motility, impotence, impaired bladder emptying, inhibition of all glands, dilated pupils, poor eye reflex, far vision.

Other They Do Not block transmission at nicotinic receptors in the skeletal NMJ. Actions depend on the prevailing autonomic tone to the target organ.

Page 18: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Hexamethonium

Class Nicotinic Receptor Antagonist

MOA Blocks transmission at all autonomic ganglia (parasympathetic and sympathetic).

Indications No longer used clinically

Side Effects Drop BP, Impaired postural reflexes, reduced renin secretion, decreased GI motility, impotence, impaired bladder emptying, inhibition of all glands, dilated pupils, poor eye reflex, far vision.

Other

Page 19: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Non Depolarising Neuromuscular

Blockers

Page 20: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Tubocurarine

Class Non depolarising Neuromuscular BlockersCompetitive

MOA Competitive neuromuscular blocking drug, bind to the nicAChR but don’t activate it, therefore cause neuromuscular block. 80-90% must be blocked for its actions to take place.

Indications Surgery to stop reflexes.

Side Effects Partial ganglion block, mild histamine release, rare hypersensitivity

Other

Page 21: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Atracurium

Class Non-depolarising Neuromuscular blockers

MOA Like tubocurarine, but with shorter duration of action. Competitive neuromuscular blocking drug, bind to the nicAChR but don’t activate it, therefore cause neuromuscular block. 80-90% must be blocked for its actions to take place.

Indications preventing reflexes in surgery

Side Effects Reduction in BP, bronchospasm, tachycardia and apnoea.

Other

Page 22: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Depolarising Neuromuscular

Blockers

Page 23: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Suxamethonium

Class Depolarising neuromuscular blockers, causing phase 1 block.

MOA Binding to and exciting postsynaptic nAChR, but for a long period of time (mins vs ms for ACh). Eventually, APs can no longer be produced because voltage sensitive Na channels have been inactivated – get flaccid paralysis.

Indications Only one used clinically because of its rapid onset and short duration of action (4 minutes)

Side Effects Initial spasms, resulting in postoperative muscle pain. Muscarinic receptor activation resulting in bradycardia. (prevented by administering atropine). Potassium release from muscle giving elevated potassium levels.

Other Some people with funny AChE may suffer NMB for hours. In myasthenia gravis don’t do anything because already have v few receptors on end plate.

Page 24: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Adrenoceptor Agonists

Directly Acting

Page 25: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Adrenaline

Class Non selective α&β adrenoceptor agonist

MOA Binds to and excites the α&β adrenoceptors, giving its actions.

Indications Acute anaphylactic reactions – inhibits mediators of immune response. Cardiac stimulant in heart block, prolongs action of local anaesthetics (vasoconstrictor). Maintain bp during spinal anaesthesia. Decrease blood flow for use in glaucoma.

Side Effects Tachycardia, arrhythmia, hypertension, cerebral haemorrhage, pulmonary oedema, low mucus secretions, tremor due to skeletal muscle effects.

Other

Page 26: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Salbutamol

Class Β2 selective Adrenoceptor Agonist

MOA Stimulates B2 receptors in the SM of the lungs and bronchi, inhibits the release of bronchoconstrictor substances from mast cells. Relative resistance to MAO and COMT

Indications Ventolin (asthma inhaler), uterine relaxation (if premature labour)

Side Effects Arrhythmias, tachycardia, vasodilation

Other Given by aerosol so limited systemic effects.

Page 27: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Dobutamine

Class Positive Chronotrope, Beta 1 adrenoceptor agonist

MOA β1 adrenoreceptors are linked to adenyl cyclase and their activation leads to increased cAMP levels, which leads to and increase in intracellular calcium and so to an increased cardiac force of contraction.

Indications CCF, all shocks, cardiomyopathy, cardiac surgery.

Side Effects Tachycardia and hypertension

Other Not to be given to tachyarrhythmic patients.

Page 28: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Isoprenaline

Class Non selective beta Adrenoceptor Agonist

MOA Simple agonist

Indications Treatment of heart block,

Side Effects Reflex tachycardia, dysrhythmias.

Other Less susceptible to uptake 1 and MAO than adrenaline.

Page 29: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Phenylephrine

Class Selective for a1 receptors

MOA Simple agonist (Relatively resistant to COMT but not MAO)

Indications Nasal decongestant (Drops/PO)Myadriatic (Eye Drops)Vasoconstrictor (IV)

Side Effects

Hypertension

Other

Page 30: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Clonidine

Class Alpha 2 selective Adrenoceptor Agonist.

MOA Reduces sympathetic tone via central brainstem action within baroreceptor pathway, to reduce sympathetic outflow.

Indications Hypertension and migraine.

Side Effects Drowsiness, hypotension

Other

Page 31: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Ephedrine

Class Indirectly acting Adrenoceptor Agonist. (promote NA release)

MOA Taken in by uptake 1 and displace NA from the vesicles. Also inhibit MAO, so displaced NA can continue to have a sympathetic effect. Potentiate actions of NA.

Indications When you need more sympathomimetic. Useful in restoring blood pressure and tissue perfusion in cases of shock. Decongestant (vasoconstriction of nasal BVs)

Side Effects Tachycardia, arrhythmias, dry mouth, cold extremities, anxiety… other α & β stimulation issues.

Other Watch out for neglecting ither things such as kidney.

Page 32: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Adrenoceptor agonists

Indirectly Acting

Page 33: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Cocaine

Class Sympathetic enhancer

MOA Strongly inhibits the reuptake of catecholamines at NAergic neurons and thus strongly enhances sympathetic activity.

Indications Abuse. Occaisionally used as a topical anaesthetic by ear, nose and throat specialists.

Side Effects Toxic psychosis, cardiac arrhythmias, hypertension, and stroke. Psychological dependence, but no real physical dependence. Chronically produces paranoid psychosis, vasoconstriction, tissue anoxia at sites of injection, damage to fetal brain. Withdrawl causes a ↓ in motor performance, restorable on provision of the drug.

Page 34: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Tyramine

Class Weak agonistMonoamine compound derived from the amino acid Tyrosine

MOA Tyramine competes with catecholamines for uptake 1, displaces NA from storage vesicles into cytosol, this leaks into the synapse and stimulates postsynaptic adrenoceptors, also competes for sites on MAO

Indications Found in the diet (Cheeses)

Side Effects

When MAO is inhibited (Antidepressants – Phenelzine) indigestion of food containing tyramine may result in a hypertensive crisis (Cheese Reaction)

Page 35: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Adrenoceptor Antagonist

Page 36: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Propranolol

Class Non selective beta adrenoceptor antagonist. Anxiolytics.

MOA Acts by antagonism at β-adrenoceptors so that excessive catecholamine release does not produce the usual sympathetic responses.

Indications Hypertension, angina, arrhythmias, good at alleviating signs of sympathetic arousal, such as palpitations, tremor, sweating and diarrhoea. Also useful in socially anxious people or musicians with stage fright.

Side Effects Bradycardia, heart failure, bronchospasm, peripheral vasoconstriction

Other Not in people with asthma or heart failure.

Page 37: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Class Negative chronotrope and inotropes, beta blocker, beta 1 selective

MOA Competitive antagonist for beta 1 adrenoceptor so reduces sympathetic innervation of the heart. Lowers tachycardia and force of contraction.

Indications Given after MI, hypertension, prophylaxis, anti-arrhythmia, thyrotoxicosis, glaucoma and anxiety

Side Effects Bronchospasm, bradycardia, heart block, hypotension

Other At high doses loses selectivity, so caution for asthmatics. Not in bradycardia, hypotension, AV block, and CCF

Atenolol

Page 38: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Labetalol

Class Alpha/beta blocker Adrenoceptor antagonist

MOA Lowers BP by a reduction of peripheral resistance. This is via blockade of α1 in blood vessels and β1 effects on neurotransmitter renin release. No change in HR or CO

Indications Hypertension

Side Effects Postural hypotension

Other

Page 39: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Phentolamine

Class Non selective α antagonist.

MOA Causes vasodilation and a fall in BP due to blockade of α1/2 receptors.

Indications hypertension

Side Effects Increased GI motility, so diarrhoea a common problem.

Other Blockade o f α receptors tend to increase noradrenaline release (enhances the reflex tachycardia seen with any bp lowering agent)

Page 40: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Doxazosin

Class α1 adrenoceptor antagonist.

MOA Cause inhibition of α1 adrenoceptor mediated vasoconstriction, so reducingPVR and venous pressure. Also lower LDL, VLDL, and TGA, and increase HDL, reducing risk of CAD

Indications Hypertension, (esp with CCF), prostate hyperplasia (reduced bladder and prostate resistance) and CAD.

Side Effects Postural hypotension, dizziness, headache and fatigue, weakness palpitations, and nausea.

Other

Page 41: Jamie Manuell Year 2 Pharmacology & Therapeutics.

False Transmitters

Page 42: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Methyldopa

Class False transmitter, antihypertensive agent

MOA Taken up by NAergic neurons, where decarboxylated and hydroxylated to form α methyl NA. Not metabolised by MAO, so shunts NA from synaptic vesicles. Release as NA but less active that NA on post α1 receptors, so less vasoconstriction, and more active on presynaptic α2 receptor. Stimulates vasopressor centre to inhibit sympathetic outflow.

Indications Renal blood flow well maintained so a good hypertensive in patients with renal insufficiency. Good in pregnancy as has no adverse effects on foetus.

Side Effects Dry mouth, sedation, postural hypotension, male sexual dysfunction, liver looks like hepatitis. Orthostatic hypotension.

Other

Page 43: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs and the Heart &

Vasculature

Page 44: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Positive Chronotropes

Page 45: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Digoxin

Class Positive Chronotrope (cardiac glycoside)

MOA These act by inhibiting the membrane Na+/K+ ATPase pump. This raises intracellular Na, decreasing Na gradient, meaning less Ca is pumped out in the Ca/Na exchanger. Ca levels increase, and so does force of contraction. Stimulation of vagus shorten atrial AP. They decrease HR, and reduce AV conductance for use in arrhythmias.

Indications Heart failure and superventricular arrhythmias.

Side Effects At high doses they raise Sym stimulation causing arrhythmias and heart block. Nausea, vomitting, visual disturbances, ab pain, diarrhoea.

Other Contraindications are heart block and hypokalaemia. Narrow therapeutic window. In toxicity, potassium supps and anti-arrhythmics given.

Page 46: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Dobutamine

Class Positive Chronotrope, Beta 1 adrenoceptor agonist

MOA β1 adrenoreceptors are linked to adenyl cyclase and their activation leads to increased cAMP levels, which leads to and increase in intracellular calcium and so to an increased cardiac force of contraction.

Indications CCF, all shocks, cardiomyopathy, cardiac surgery.

Side Effects Tachycardia and hypertension

Other Not to be given to tachyarrhythmic patients.

Page 47: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Milrinone

Class Positive chronotrope, Phosphodiesterase II inhibitor

MOA Phosphodiesterase is responsible for the degradation of cAMP. Inhibiting this raises cAMP levels, so contractility and vasodilation

Indications Severe acute heart failure, resistant to other drugs.

Side Effects Nausea, vomiting, arrhythmias, liver dysfunction, abdo pain, hypersensitivity.

Other Developed to get around adverse effects with cardiac glycosides.

Page 48: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Negative Chrono and Inotropes

Page 49: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Class Negative chronotrope and inotropes, beta blocker, beta 1 selective

MOA Competitive antagonist for beta 1 adrenoceptor so reduces sympathetic innervation of the heart. Lowers tachycardia and force of contraction.

Indications Given after MI, hypertension, prophylaxis, anti-arrhythmia, thyrotoxicosis, glaucoma and anxiety

Side Effects Bronchospasm, bradycardia, heart block, hypotension

Other At high doses loses selectivity, so caution for asthmatics. Not in bradycardia, hypotension, AV block, and CCF

Atenolol

Page 50: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Diltiazem

Class Negative chronotrope and inotrope, rate limiting calcium channel blocker

MOA These bind to and inhibit opening of the L-type calcium channels. This causes arterial vasodilation, so reducing cardiac workload. Has –ve chronotropic and inotropic effects

Indications Indications are prophylaxis and treatment of angina and hypertension. Verapamil and diltiazem are given for supraventricular arrhythmias

Side Effects can cause flushing, headaches, hypotension, ankle swelling, CCF, heart block, constipation

Other Not to be given to patients in cardiogenic shock, severe heart failure, those taking beta-blockers, and severe bradycardia.

Page 51: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Verapamil

Class Negative chronotropes and inotrope, Rate limiting calcium channel blockers

MOA These bind to and inhibit opening of the L-type calcium channels. This causes arterial vasodilation, so reducing cardiac workload. Has –ve chronotropic and inotropic effects

Indications Indications are prophylaxis and treatment of angina and hypertension. Verapamil and diltiazem are given for supraventricular arrhythmias

Side Effects can cause flushing, headaches, hypotension, ankle swelling, CCF, heart block, constipation

Other Not to be given to patients in cardiogenic shock, severe heart failure, those taking beta-blockers, and severe bradycardia.

Page 52: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs reducing Preload & Afterload

Page 53: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Ramipril /Enalapril

Class Ace Inhibitor to reduce preload and afterload

MOA These work by preventing angiotensin I to Angiotensin II, meaning that the ATI receptors in the arterioles and in the adrenal cortex are not triggered, resulting in increased water and sodium excretion in the kidney

Indications Indications are in CVD, such as hypertension, post MI, Diabetic neuropathy, Progressive renal insufficiency, patients at high risk of CVD.

Side Effects Adverse effects are hypotension, dry cough and angioedema.

Other Not in pregnancy, renovascular disease, aortic stenosis

Page 54: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Captopril

Class Ace inhibitor

MOA These work by preventing angiotensin I to Angiotensin II, meaning that the ATI receptors in the aterioles and in the adrenal cortex are not triggered, resulting in increased water and sodium excretion in the kidney

Indications Indications are in CVD, such as hypertension, post MI, Diabetic neuropathy & nephropathy, Progressive renal insufficiency, patients at high risk of CVD.

Side Effects Adverse effects are hypotension, dry cough and angioedema.

Other Not in pregnancy, renovascular disease, aortic stenosis

Page 55: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Losartan

Class Angiotensin receptor blocker

MOA Cause inhibition at the angitensin II receptor, resulting in vasodilation with reduction in PVR.

Indications Hypertension

Side Effects Cough, orthostatic hypotension, dizzyness, headache, fatigue, hyperkalaemia and rash.

Other Contraindications in breastfeeding, pregnancy. Caution in renal artery stenosis and aortic stenosis.

Page 56: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Nicorandil

Class Organic nitrate (reducing preload and afterload). Potassium channel activator

MOA Activates potassium channels of vascular SM. Potassium flows out of the cells causing hyperpolarisation. This inhibits the influx of calcium, so inhibits contraction – hence vasodilation.

Indications Prophylaxis of angina

Side Effects Headache, cutaneous vasodilation, nausea and vomiting

Other Cardiogenic shock, left ventricular failure, hypotension.

Page 57: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Bendrafluazide

Class Thiazide diuretic

MOA These act on the early distal tubule. They inhibit the Na/Cl cotransporter in the luminal membrane. They increase secretion of K and protons into the collecting ducts, but decrease Ca excretion.

Indications Hypertension, oedema 2ndary to CCF, liver disease, or nephrotic syndrome. Sometimes for prophylaxis of calcium containing renal stones.

Side Effects Hypokalaemia, hyperuricaemia, hyponatraemia, hypercalcaemia, and metabolic acidosis.

Other Shouldn’t be used in those taking cardiac glycosides, or diabetes mellitus (as may cause hyperglycaemia). Or in hypokalaemia, hyponatraemia, or hypercalcaemia.

Page 58: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Spironalactone

Class Aldosterone antagonist.

MOA Inhibits the sodium retaining effects of aldosterone.

Indications It is useful in heart failure and resistant cases of hypertension.

Side Effects Can cause hyperkalaemia due to sodium retention, and steroid like side effects like gynaecomastia, menstrual disorders, and testicular atrophy.

Other Due to +ve feedback, more aldosterone may be produced, increasing unwanted side effects. Doesn’t prevent aldosterone production.

Page 59: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs to control or correct

Dysrhythmias

Page 60: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Amiodarone

Class Wide spectrum anti-arrhythmic, potassium channel blockers.

MOA These are potassium channel blockers which prolong cardiac action potential duration, and the refractory period. It also blocks sodium and calcium channels, and blocks β and α adrenoceptors.

Indications For ventricular and supraventricular arrhythmias.

Side Effects Can cause arrhythmias, thyroid dysfunction, liver damage, pulmonary disorders, photosensitivity and neuropathy.

Other Not to be given to those with AV block, sinus bradycardia, or thyroid dysfunction

Page 61: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Diltiazem

Class Negative chronotrope and inotrope, rate limiting calcium channel blocker

MOA These bind to and inhibit opening of the L-type calcium channels. This causes arterial vasodilation, so reducing cardiac workload. Has –ve chronotropic and inotropic effects

Indications Indications are prophylaxis and treatment of angina and hypertension. Verapamil and diltiazem are given for supraventricular arrhythmias

Side Effects can cause flushing, headaches, hypotension, ankle swelling, CCF, heart block, constipation

Other Not to be given to patients in cardiogenic shock, severe heart failure, those taking beta-blockers, and severe bradycardia.

Page 62: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Verapamil

Class Negative chronotropes and inotrope, Rate limiting calcium channel blockers

MOA These bind to and inhibit opening of the L-type calcium channels. This causes arterial vasodilation, so reducing cardiac workload. Has –ve chronotropic and inotropic effects

Indications Indications are prophylaxis and treatment of angina and hypertension. Verapamil and diltiazem are given for supraventricular arrhythmias

Side Effects can cause flushing, headaches, hypotension, ankle swelling, CCF, heart block, constipation

Other Not to be given to patients in cardiogenic shock, severe heart failure, those taking beta-blockers, and severe bradycardia.

Page 63: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Digoxin

Class Positive Chronotrope (cardiac glycoside)

MOA These act by inhibiting the membrane Na+/K+ ATPase pump. This raises intracellular Na, decreasing Na gradient, meaning less Ca is pumped out in the Ca/Na exchanger. Ca levels increase, and so does force of contraction. Stimulation of vagus shorten atrial AP. They decrease HR, and reduce AV conductance for use in arrhythmias.

Indications Heart failure and superventricular arrhythmias.

Side Effects At high doses they raise Sym stimulation causing arrhythmias and heart block. Nausea, vomitting, visual disturbances, ab pain, diarrhoea.

Other Contraindications are heart block and hypokalaemia. Narrow therapeutic window. In toxicity, potassium supps and anti-arrhythmics given.

Page 64: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Class Negative chronotrope and inotropes, beta blocker, beta 1 selective

MOA Competitive antagonist for beta 1 adrenoceptor so reduces sympathetic innervation of the heart. Lowers tachycardia and force of contraction.

Indications Given after MI, hypertension, prophylaxis, anti-arrhythmia, thyrotoxicosis, glaucoma and anxiety

Side Effects Bronchospasm, bradycardia, heart block, hypotension

Other At high doses loses selectivity, so caution for asthmatics. Not in bradycardia, hypotension, AV block, and CCF

Atenolol

Page 65: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Coronary Vasodilators

Page 66: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Diltiazem

Class Negative chronotrope and inotrope, rate limiting calcium channel blocker

MOA These bind to and inhibit opening of the L-type calcium channels. This causes arterial vasodilation, so reducing cardiac workload. Has –ve chronotropic and inotropic effects

Indications Indications are prophylaxis and treatment of angina and hypertension. Verapamil and diltiazem are given for supraventricular arrhythmias

Side Effects can cause flushing, headaches, hypotension, ankle swelling, CCF, heart block, constipation

Other Not to be given to patients in cardiogenic shock, severe heart failure, those taking beta-blockers, and severe bradycardia.

Page 67: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Verapamil

Class Negative chronotropes and inotrope, Rate limiting calcium channel blockers

MOA These bind to and inhibit opening of the L-type calcium channels. This causes arterial vasodilation, so reducing cardiac workload. Has –ve chronotropic and inotropic effects

Indications Indications are prophylaxis and treatment of angina and hypertension. Verapamil and diltiazem are given for supraventricular arrhythmias

Side Effects can cause flushing, headaches, hypotension, ankle swelling, CCF, heart block, constipation

Other Not to be given to patients in cardiogenic shock, severe heart failure, those taking beta-blockers, and severe bradycardia.

Page 68: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Glyceryl Trinitrate

Class Organic Nitrates

MOA Release NO which activates Guanylate cyclase causing more cGMP and more Ca storage in the SR, hence Venodilation which reduces preload and therefore SV and CO, also coronary vessel vaso-d

Indications Angina

Side Effects

Venodilation causes Postural hypotension, dizziness, syncope and reflex tachy. Arterial dilation causes throbbing headaches and flushing

Other

Page 69: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Minoxidil

Class K+ channel opener

MOA Potent vasodilator acting on arteries and arterioles by opening potassium channels in SM and causing hyperpolarisation.

Indications Used in hypertension control in pregnancy

Side Effects In the absence of β blockade it causes reflex tachycardia.

Other

Page 70: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Doxazosin

Class α1 adrenoceptor antagonist.

MOA Cause inhibition of α1 adrenoceptor mediated vasoconstriction, so reducingPVR and venous pressure. Also lower LDL, VLDL, and TGA, and increase HDL, reducing risk of CAD

Indications Hypertension, (esp with CCF), prostate hyperplasia (reduced bladder and prostate resistance) and CAD.

Side Effects Postural hypotension, dizziness, headache and fatigue, weakness palpitations, and nausea.

Other

Page 71: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Vasoconstrictors

Page 72: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Sumitriptan

Class Agonist at 5HT1D receptors

MOA Causes vasoconstriction at some large arteries and inhibits trigeminal nerve transmission,

Indications Used to treat migraine attacks

Side Effects Sensation of tingling, heat, chest tightness

Other Contraindicated in patients with CAD as it causes coronary vasoconstriction, hepatic impairment, pregnancy and breastfeeding.

Page 73: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anti-Thrombotic & Anticoagulant

s

Page 74: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Thrombolytics (Fibrinolytics)

Page 75: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Streptokinase

Class Tissue plasminogen activator

MOA This forms a complex with and activates plasminogen into plasmin, a fibrinolytic enzyme

Indications Life threatening venous thrombosis, pulmonary embolism, arterial thromboembolism, and acute MI.

Side Effects Nausea, vomiting and bleeding. Derived form streptococcus, therefore antigenic. Repeated administration could result in anaphylaxis.

Other Not for use in recent haemorrhage, trauma, surgery or any form of Cerebrovascular disease.

Page 76: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Alteplase

Class Tissue type plasminogen activator

MOA Binds with and activates plasminogen into plasmin, which breaks down fibrin in a clot.

Indications Useful as a fibrinolytic if the antigenic streptokinase has already been administered once, as it is non antigenic. MI, Pulmonary embolism

Side Effects Nausea, vomiting, and bleeding

Other Same as streptokinase, ie any patient who has recently suffered a trauma likely to have required clot formation.

Page 77: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anticoagulants

Page 78: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Warfarin

Class Vitamin K antagonist

MOA Vitamin K is vital in the post transcriptional γ-carboxylation of glutamic acid residues of prothrombin (factor II) and clotting factors VII, IX, and X by the liver. This stops clotting cascade

Indications Warfarin can be used in treatment of DVT and pulmonary embolism, prophylaxis of embolisation in atrial fibrillation and rheumatic disease and in patients with prosthetic heart valves

Side Effects haemorrhage

Other Warfarin only affects new factors so takes 72 hrs to take effect. Should not be used in Cerebral thrombosis, peripheral arterial occlusion, peptic ulcers, hypertension, pregnancy

Page 79: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Heparin

Class Anticoagulant

MOA Heparins work by activating antithrombin III, which inactivates thrombin and factor X. It also inhibits platelet aggregation

Indications Heparin and LMWH given in thrombosis and pulmonary embolism, MI, prophylaxis against PO DVT and pulmonary embolism in high risk patients.

Side Effects haemorrhage

Other Action is immediate so can be used in emergency. Should not be used in haemophilia, thrombocytopenia, or peptic ulcers.

Page 80: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anti-Platelet Drugs

Page 81: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Aspirin

Class Cyclo-oxygennase inhibitor.acetylates the active site.

MOA This inhibits the COX enzymes, which in turn inhibit production of thromboxane A2, preventing platelet aggregation. Also inhibits PGE2, making it an analgesic. COX-2 is proinflammatory.

Indications In overdose can uncouple oxidative phosphorylation, causing metabolic acidosis.

Side Effects Stomach ulcers, bronchoconstriction. Arachidonic acid either forms PGs with COX, or Leukotrienes with lipoxygenase. LT4 is a powerful bronchoconstrictor, more produced if COX inhibited. Asthmatics vulnerable. Reduced creatinine clearance, possible nephritis. Bad because effects COX-1 200 fold more than COX-2.

Other Effects vary according to dose. Asthmatics can’t take them. Aspirin also displaces wafarin from plasma causing bleeding, as warfarin normally 5% unbound.

Page 82: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Clopidigrel

Class Anti platelet aggregation drug.

MOA Clopidogrel inhibits activation of the IIb/IIIa receptor on the surface of platelets, required for aggregation to occur.

Indications Used if patient truly allergic to aspirin. Secondary prevention of CVD.

Side Effects Haemorrhage, ab discomfort, nausea and vomiting.

Other

Page 83: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Abciximab

Class Glycoprotein IIb/IIIa inhibitor

MOA It is an antibody fragment antagonist of the glycoprotein IIb/IIIa receptor on platelets. This prevents aggregation.

Indications Used if problems with other ones. Ischaemic cardiac complications in open heart surgery. Short term prevention of MI in unstable angina.

Side Effects Haeorrhage, nausea, vomiting hypotension.

Other Single administration because it is antigenic, potential anaphylaxis if second administration

Page 84: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Statins

Page 85: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Simvastatin

Class HMG-CoA Reductase Inhibitor

MOA Catalyses the enzyme that is the rate limiting step in Cholesterol synthesis in the Liver, the fall in circulating Cholesterol then causes up regulation of LDL receptors on hepatocytes cell surfaces, also reduces circulating VLDL’s and TG’s

Indications Hyperlipidaemia

Side Effects

GI upsetsCNS effects (Dizziness, blurred vision, headache)Cause of abnormal LFT’sMyalgia if used with Fimbrates

Other Stabilizes atherosclerotic plaques and reduces inflammatory cell migration into plaques

Page 86: Jamie Manuell Year 2 Pharmacology & Therapeutics.

NSAIDS

Page 87: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Aspirin

Class Cyclo-oxygennase inhibitor.acetylates the active site.

MOA This inhibits the COX enzymes, which in turn inhibit production of thromboxane A2, preventing platelet aggregation. Also inhibits PGE2, making it an analgesic. COX-2 is proinflammatory.

Indications In overdose can uncouple oxidative phosphorylation, causing metabolic acidosis.

Side Effects Stomach ulcers, bronchoconstriction. Arachidonic acid either forms PGs with COX, or Leukotrienes with lipoxygenase. LT4 is a powerful bronchoconstrictor, more produced if COX inhibited. Asthmatics vulnerable. Reduced creatinine clearance, possible nephritis. Bad because effects COX-1 200 fold more than COX-2.

Other Effects vary according to dose. Asthmatics can’t take them. Aspirin also displaces wafarin from plasma causing bleeding, as warfarin normally 5% unbound.

Page 88: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Ibuprofen

Class NSAID, COX-2 antagonist

MOA Works as a competitive substrate for the COX-2 enzyme, preventing the arachidonic acid conversion by COX-2 into prostaglandins, and prostacyclins.

Indications Mainly for high risk GI patients who would get stomach ulcers from Aspirin. Drug of choice for inflammatory joint disease

Side Effects Very few

Other

Page 89: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Celecoxib

Class This is a selective COX-2 inhibitor

MOA Selective but expensive COX-2 inhibitor. Used for high risk GI as no COX-1 side effects. Also less effect on nephrotoxicity.

Indications High risk GI anti-inflammatory

Side Effects

Other Contraindicated in Inflammatory bowel disease.

Page 90: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Diuretics

Page 91: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Mannitol

Class An osmotic diuretic.

MOA Freely filtered at the glomerulus, but only partially reabsorbed. Means that water leaves tubule under osmosis, and more sodium is excreted, and there is less free reabsorption of water.

Indications Raised intracranial and intrtaocular pressure.

Side Effects Chills and Fever

Other Contraindicated in congestive cardiac failure, and pulmonary oedema.

Page 92: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Acetazolamide

Class Carbonic anhydrase inhibitor. Weak diuretics

MOA Acts in the proximal tubule to prevent the usual removal of Na+ and HCO3

-, water follows. Prescence of Na+ in the distal tubule also increases excretion of K+.

Indications Not normally used as diuretics but of value in the treatment of glaucoma.

Side Effects Loss of carbonate can result in metabolic acidosis.

Other

Page 93: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Frusemide

Class Loop diuretic – powerful diuretic

MOA Act on thick ascending segment of the L of H. Inhibit the Na+, K+, 2Cl- cotransporter in the luminal membrane. This dilutes the medullary interstitium and reduces the concentrating power in the collecting duct. ↑ delivery of Na to distal tubule activates Na/K exchanger. Gives ↑ urine, ↑ excretion of Na, K, Cl, Ca, Mg

Indications Acute pulmonary oedema, oedema due to heart failure, liver disease, renal disease, hypercalcaemia, hyperkalaemia, Acute renal failure

Side Effects

Metabolic acidosis, hypokalaemia, loss of Ca, Mg, hypovolaemia, hypotension, nausea, deafness, allergies.

Other

Page 94: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Bendrofluazide

Class Thiazide

MOA Inhibition of Na and Cl reabsorption in the early distal tubule. ↑ solute ↓ reabsorption of water, ↑ volume, Na, K, Cl, and Mg. Reduced loss of Ca. Also vasodilation and ↓ insulin production due to opening of K channels.

Indications Congestive Heart failure, hypertension, Idiopathic hypercalcaemia, nephrogenic diabetes insipidus

Side Effects Hypokalaemia, alkalosis, hypperglycaemia, uric acid retention (gout). Allergies, hyponatraemia.

Other

Page 95: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Spironalactone

Class Aldosterone antagonists, potassium sparing diuretic.

MOA This is a competitive antagonist at aldosterone receptors, ↓ Na reabsorption, and ↓ potassium and proton secretion. Mild diuresis, excretion of 2-3% of Na.

Indications Heart failure and resistant cases of hypertension

Side Effects Hyperkalaemia due to sodium retention, and steroid like effects like gynaecomastia, menstrual disorders, and testicular atrophy.

Other

Page 96: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Amiloride

Class Potassium sparing diuretic, Sodium Channel Blocker, distal tubule

MOA These block sodium reabsorption by the principal cells, thus reducing the potential difference across the cell, and ↓ potassium secretion

Indications With K losing diuretics to prevent K loss. Primary and secondary hyperkalaemia.

Side Effects Better tolerated than spironalactone. Hyperkalaemia, hyponatraemia, GI disturbances.

Other

Page 97: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anti-Emetics

Page 98: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Promethazine(Remember Promet-

h-azine)

Class Anti-emetic (phenothiazine derivative) H1>M>D2

MOA Acts as a competitive antagonist at histaminergic (H1), cholinergic (M), and dopaminergic receptors. (Mostly H1). It acts centrally (Labyrinth, NTS, vomiting centre) to block activation of the vomiting centre.

Indications Motion sickness (prophylaxis), labyrinth disorders (ie Meniere’s disease), morning sickness, pre and post operatively. Sedative and anti muscarinic actions are also useful.

Side Effects Dizziness, fatigue, Tinnitus, sedation, Excitation in excess, convulsions, Antimuscarinic side effects.

Other

Page 99: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Metoclopramide (Remember metoclopromi-

d-e)

Class Anti-emetic. Receptor antagonist. D2>>H1>>M

MOA Acts on D2 receptors, especially centrally at the central trigger Zone. Acts in the GI tract ↑ in SM motility, ↑ in Gastric emptying.

Indications Nausea and vomiting associated with uraemia, radiation sickness, GI disorders, Cancer chemotherapy like cisplatin.

Side Effects Drowsiness, dizziness, anxiety, extrapyramidal reactions, no anti-psychotic reactions unlike other D antagonists.

Other Competes with other drugs. Adsorption and effectiveness of digoxin is ↓. Accelerate GI may cause nutrient deficiency.

Page 100: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Class Muscarinic Receptor Antagonist, antiemetic

MOA Binds to receptor making it inaccessible for ACh to activate receptor. Emetic actions in vest. Nuclei, NTS, vomiting centre, to block VC’s activation.

Indications Used to prevent bronchial secretions and salivations.protect heart from arrhythmias, particularly those caused by neuromuscular blockers. Prevention of motion sickness, parkinson’s disease.

Side Effects Dry mouth and skin, raised body temperature, dilatation of pupil, relaxation of ciliary msucle (no accomodation) urinary retention, irritability and hyperactivity. Drowsiness, slow gut movement.

Other Different tissues have different levels of responsiveness. Salivary, sweat, bronchial>parietal cells production of gastric acid.

Hyoscine (Scopolamine)

Page 101: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Ondansetron (Remember ondan-s-

etron)

Class Anti emetic, 5HT3 (Serotonin) receptor antagonist.

MOA Blocks 5HT3 receptors in visceral afferents and central trigger zone

Indications Anti emetic in chemotherapy induced vomiting, especially cisplatin. Radiotherapy induced sickness, PO nausea and vomiting.

Side Effects Headache, sensation of flushing and warmth, increased large bowel transit time (constipation) due to 5HT3 receptor block.

Other

Page 102: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs used for Gastric &

Duodenal Ulcers

Page 103: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Antimicrobials

Page 104: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Metronidazole

Class Antiprotozoal and antibacterial against anaerobic bacteria. Antibiotic to eliminate helicobacter pylori – bactericidal.

MOA Metabolised to an intermediate that inhibits bacterial DNA synthesis and degrades existing DNA. Selective because intermediate form is not produced in mammalian cells.

Indications Helicobacter pylori eradication in peptic ulcer sufferers.

Side Effects Mild headache and GI disturbance. ADRs with alcohol

Other Not to pregnant women

Page 105: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Amoxycillin

Class Broad spectrum Penicillin antibiotic.

MOA Inihibit bacterial wall synthesis. They bind to penicillin binding proteins. This results in inhibition of peptide crosslinking within the cell wall, and indirect activation of autolytic enzymes, resultant lysis.

Indications Broad spectrum so loads of applications. Used in eradication of helicobacter pylori in peptic ulceration.

Side Effects Specific and safe but possible hypersensitivity reactions inc. rashes and anaphylaxis. Diarrhoea common, neurotoxicity at ↑ CSF levels.

Other Not for known hypersensitivity sufferers. Resistance can be due to microbial production of a β-lactamase enzyme which breaks the β-lactam ring of penicillins.

Page 106: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Clarithromycin

Class Macrolide. Bactericidal/bacteriostatic.

MOA They bind to the bacterial ribosome, preventing the translocation movement of the ribosome along mRNA. Inhibits translocation of bacterial tRNA.

Indications Good against gram +ve bacteria and spirochaetes. Haemophilus influenzae, mycobacterium avium cellulare, and helicobacter pylori.

Side Effects GI disturbance

Other Resistance due to alteration of binding site of ribosome.

Page 107: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Inhibitors of Gastric Acid Secretion

Page 108: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Omeprazole

Class Proton pump inhibitor in Peptic ulceration.

MOA Prodrug converted in acidic pH to sulphonamide, which binds covalently to the suphydryl groups on H+/K+ATPase responsible for gastric acid secretion. Inihibit acid secretion by >90%. Is a weak base so attracted to acidic areas like cannaliculi of parietal cells. Prevents widespread actions.

Indications Peptic ulceration, reflux oesophagitis, H2 receptor antagonist resistant patients.

Side Effects GI upset, nausea, headaches. Potential gastric atrophy

Other

Page 109: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Cimetidine ranitidine

Class H2 receptor antagonists.

MOA Block actions of histamine on parietal cells

Indications First line treatment of GORD and peptic ulcer disease.

Side Effects Dizziness, fatigue, gynaecomastia, and rash

Other Less effective than PPIs at healing ulcers (60% ↓ in acid secretion). Inhibits p450 enzymes, so not to be administered with warfarin, phenytoin, and theophylline.

Page 110: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Cytoprotective Drugs

Page 111: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Sucralfate

Class Polymer containing aluminium hydroxide and sucrose octa-sulphate. Cytoprotective drugs.

MOA It acquires a strong negaitve charge in acidic environment. Binds to +ve proteins forming a protective gel over the ulcer, not allowing peptins or acids to damage. ↑ mucus, PGs and HCO3-, ↓ helicobacter pylori.

Indications Peptic ulcer.

Side Effects Can cause constipation and may ↓ absorption of many other drugs (ie antibiotics) through stomach wall.

Other

Page 112: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Bizmuth chelate

Class Polymer structure as with sucralfate

MOA Forms protective gel over ulcer

Indications Peptic ulcer disease

Side Effects Constipation, ↓ absorption of other drugs through wall.

Other

Page 113: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Misoprostol

Class PGE1 analogue

MOA Mimics actions of PGE1 which stimulates mucus secretions in the gastroduadenal lining.

Indications Peptic ulcer disease

Side Effects Diarrhoea, uterine contractions, ab cramps.

Other May be co prescribed with NSAIDs to counteract their anti PG effect chronically and prevent peptic ulcers.

Page 114: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs for Inflammatory

Bowel Disease

Page 115: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Glucocorticoids

Page 116: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Hydrocortisone

Class Natural glucocorticoid with some mineralocorticoid actions.

MOA Move into cells where they activate glucocorticoid receptors. These receptors are translocated to the DNA where they cause transcription of corticosteriod responsive genes. These have diverse effects on target tissues. See prednisolone. Can also turn off genes (reduced antigen presentation, reduced production of adhesion molecules, COX, NO, cytokines such as IL-1 and TNFα)

Indications IBD (crohn’s, Ulcerative colitis), Anti-inflammatory, immunosuppression

Side Effects Cushing like appearance. See separate slide. Adrenal suppression and atrophy.

Other Withdraw slowly to avoid adrenal insufficiency crisis. Normal markers of infection suppressed so must be aware.

Page 117: Jamie Manuell Year 2 Pharmacology & Therapeutics.

prednisolone

Class Synthetic glucocorticoid. Anti-inflammatory, immunosuppressant.

MOA These induce lipocortin which inhibits the conversion of membrane phosphilipid to arachidonic acid by phospholipase A2. Leukotrienes and prostanoids are therefore not produced, suppressing inflammation and chemotaxis of immune agents.

Indications IBD (crohn’s, UC)

Side Effects As for hydrocortisone.

Other

Page 118: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Budesonide

Class Synthetic glucocorticoid. Anti-inflammatory, immunosuppressant.

MOA Budesonide in comparison with prednisolone has been associated with fewer bone density losses and unlike other corticosteroids has little influence on the hypothalamic-pituitary-adrenal axis which also limit the need of tapering before discontinuation. Overall, it has a lower incidence of systemic manifestations than similar medications.

Indications IBD (crohn’s, UC)

Side Effects

As for hydrocortisone.

Other

Page 119: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Aminosalicylates

Page 120: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Sulfasalazine

Class Aminosalicylate

MOA Broken down in the gut to 5-ASA. These scavenge free radicals. Fewer anti-inflammatory actions and no immunosuppressive ones. AI actions are ↓ inflammatory cytokine production, ↓ PG and LT, ↓ leukocyte infiltration. Activated by gut flora from moiety.

Indications Maintain remission and prevent relapse of inflammatory bowel conditions

Side Effects Sulfaphrindine (non active part of sulfasalazine) reaponsible for Nausea, vomiting, headache and rashes., hypospermia, anorexia

Other Not to people with renal impairment, or salicylate intolerance

Page 121: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Mesalazine

Class Aminosalicylate (5-ASA)

MOA Same as sulfasalazine, but without nasty side effects.

Indications Inflammatory bowel syndrome.

Side Effects Few, no sulfapyridine to worry about.

Other

Page 122: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Immunosupressants

Page 123: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Azothioprine

Class Immunosuppressive

MOA Activated by gut flora to 6 metcaptopurine, a purine analogue, interferes with DNA synthesis. Inihibits cell replication, cell and antibody mediated immune reponses, lymphocyte proliferation, mononuclear cell infiltration, synthesis of antibodies.

Indications Inflammatory bowel syndrome. Used to maintain remission in CD

Side Effects

Other More effective than other immunosuppressives so can get away with fewer GCs. Not good in gout treatment because it is metabolised by Xanthine Oxidase (target of gout treatment).

Page 124: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anti-TNFα

Page 125: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Imfliximab

Class

MOA Crohn’s is a type 1 autoimmune response. TNF-α plays an important role in pathogenesis. Anti reduces activation of anti-TNFα receptors in the gut. Promotes apoptosis of activated T-cells.

Indications Inflammatory bowel disease and other Th1 mediated AI diseases

Side Effects ↑ incidence of extra pulmonary TB. Worsening of heart failure, can be immunogenic, specialist use.

Other 1 IV every 8 weeks

Page 126: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs used in Respiratory

Disease

Page 127: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Salbutamol

Class Β2 selective Adrenoceptor Agonist

MOA Stimulates B2 receptors in the SM of the lungs and bronchi, inhibits the release of bronchoconstrictor substances from mast cells. Relative resistance to MAO and COMT

Indications Ventolin (asthma inhaler), uterine relaxation (if premature labour)

Side Effects Arrhythmias, tachycardia, vasodilation

Other Given by aerosol so limited systemic effects.

Page 128: Jamie Manuell Year 2 Pharmacology & Therapeutics.

salmeterol

Class β-2 receptor agonist

MOA Stmiulation of β2 receptors in the airway SM leads to rise in intracellular cAMP levels and SM relaxation. Also prevent mast cell activation. This has potent β2 effects but limited β1 actions, so fewer cardiac side effects.

Indications Alone to treat mild asthma and bronchospasm, but more often with corticosteroids

Side Effects Fine tremor, tachycardia and hypokalaemia after high doses.

Other Not in hyperthyroidism, CVD, arrhythmias.

Page 129: Jamie Manuell Year 2 Pharmacology & Therapeutics.

aminophylline

Class Phosphodiesterase inhibitor

MOA Acts by raising the cAMP levels (which relaxes SM), by inhibiting phosphodiesterase, the enzyme responsible for converting cAMP to AMP. Aminophylline is the IV xanthine used in severe asthma attacks.

Indications Status asthmaticus

Side Effects Nausea, vomiting, tremor, insomnia, and tachycardia.

Other Not often used because PDE exists everywhere in the body, cAMP is very common. Not for use in CVD, hypertension, hepatic impairment, have many drug interactions.

Page 130: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Ipratropium Bromide

Class Muscarinic Receptor Antagonist, parasympatholytic

MOA Inhaled, blocks action of acetylcholine.

Indications Used in bronchodilation. For asthma and obstructive airways disease.

Side Effects Systemic effects of blocking muscarinic cholinoceptors.

Other

Page 131: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs of Abuse

Page 132: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Opiates

Page 133: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Morphine

Class Strong opioid analgesic

MOA Acts on opiate receptors. These exist in the dorsal horn relay neurones, descending inhibitory NA fibres from the brainstem, and descending seratonergic fibres from the brainstem, all of which block sensory information from travelling in the dorsal column, leading to analgesia.

Indications Drug of choice for severe pain in terminal care.

Side Effects Drowsiness and sedation – initial excitement followed by sedation and coma (in OD). ↓ in sensitivity of resp centre to CO2 leading to shallow and slow respiration, tolerance and dependence, suppression of cough (antitussive), vomiting due to CTZ stimulation, pupillary constriction due to stimulation of parasympathetic 3rd CN nucleus, hypotension and ↓ CO, due to reduced hypothalamic sympathetic outflow. Bronchospasm, flushing and arteriolar dilation due to histamine release.

Page 134: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Heroin(dimorphine)

Class Opioid drug of abuse, sometimes analgesic

MOA Acts on opioid receptors. Twice as potent as morphine owing to its greater penetration of the BBB, metabolised to morphine in the body.

Indications Severe pain, post operative, MI and acute pulmonary oedema. Not used as much as morphine due to added euphoria and dependence.

Side Effects Causes less nausea and hypotension than morphine, but more euphoria.

Other

Page 135: Jamie Manuell Year 2 Pharmacology & Therapeutics.

codeine

Class Weak opioid analgesic

MOA Acts on opioid receptors. Only 1/12 analgesic potency of morphine.

Indications Mild to moderate pain, Anti-tussive and anti diarrhoeal effects (taking advantage of side effects).

Side Effects Nausea and constipation

Other

Page 136: Jamie Manuell Year 2 Pharmacology & Therapeutics.

methadone

Class Long acting opioid analgesic.

MOA Acts on opioid receptors. Withdrawl symptoms are more prolonged but less intense than withdrawl from heroin.

Indications Weaning opioid addicts from their addiction

Side Effects As opioid general ADRs, but not too marked.

Other

Page 137: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Opiate Receptor Antagonists

Page 138: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Naloxone

Class Opiate receptor antagonist

MOA Acts as a competitive inhibitor at opiate receptors.

Indications Used in heroin or other opioid overdose IV, along with respiratory support.

Side Effects

Other

Page 139: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Reuptake Inhibitors

Page 140: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Cocaine

Class Sympathetic enhancer

MOA Strongly inhibits the reuptake of catecholamines at NAergic neurons and thus strongly enhances sympathetic activity.

Indications Abuse. Occaisionally used as a topical anaesthetic by ear, nose and throat specialists.

Side Effects Toxic psychosis, cardiac arrhythmias, hypertension, and stroke. Psychological dependence, but no real physical dependence. Chronically produces paranoid psychosis, vasoconstriction, tissue anoxia at sites of injection, damage to fetal brain. Withdrawl causes a ↓ in motor performance, restorable on provision of the drug.

Page 141: Jamie Manuell Year 2 Pharmacology & Therapeutics.

MethyleneDioxyMethAmpetamine

(ecstasy)

Class Serotonin (5-hydroxytryptamine) reuptake inhibitor

MOA Release of monoamines, inhibition of monoamine uptake. Especially acts on serotonergic neurons, potentiating 5-HT.

Indications Drug of abuse

Side Effects Stimulant and hallucinogenic properties, euphoria, arousal, and perceptual disturbances are common. Feelings of euphoric empathy so that social barriers are reduced. Withdrawl like amphetamines. Toxicity results in hyperthermia, exhaustion, dehydration. Seratonergic neurodegeneration chronically.

Page 142: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Alcohol

Page 143: Jamie Manuell Year 2 Pharmacology & Therapeutics.

EthanolClass Alcohol

MOA Acts as a volatile anaesthetic agent producing general CNS depression. Cellular mechanisms involve inhibiting calcium entry, and so reducing NT release, as well as potentiation of GABA transmission.

Indications Antidote to methanol poisoning.

Side Effects Physical and psychological dependence occur. Withdrawl hangover. Late stage involves delirium, tremor, hallucinations, and confusion. Acute toxicity causes ataxia, nystagmus, coma, resp. depression, and death. Chronically causes neurodegeneration (worsened by vit deficiency), dementia, liver damage, pancreatitis, and accompanying depression. ↓ vasopressin secretion causing diuresis and delayed parturition at term due to inhibitory effects at the hypothalamus. Action at ant. Pit. Causes ACTH production leading to adrenal steroid production. This leads to feminisation in males. Helped by enhanced testosterone inactivation in the liver.

Page 144: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Ethanol Aversion Therapy

Page 145: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Disulfiram

Class

MOA Inhibits action of Acetaldehyde dehydrogenase and so inhibits conversion of Acetaldehyde to Acetic acid

Indications Ethanol aversion therapy

Wanted Side Effects

flushing of the skin, accelerated heart rate, shortness of breath, nausea, vomiting, throbbing headache, visual disturbance, mental confusion, postural fainting and circulatory collapse

Other

Page 146: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Antimicrobial Drugs

Page 147: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs which interfere with the

synthesis / action of Folate

Page 148: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Sulfamethoxazole

Class Sulfonamide – anti folate

MOA Folate necessary to make DNA. Man has uptake processes, bacteria have to produce theirs, and need p-aminobenzoic acid. Sulfonamide is an analogue of this, meaning it isn’t produced, so bacteria can’t replicate. Bacterostatic, then host system can erradicate infection.

Indications Not used much except in co-trimoxazole.

Side Effects Nausea &vomiting, headache, mental depression. Potential severe: hepatitis, hypersensitivity, bone marrow suppression.

Other Widespread resistance to these drugs.

Page 149: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Trimethoprim

Class Folate antagonist.

MOA Inhibits Dihydrofolate reductase, an enzyme which is more sensitive in bacteria to interference. DNA is stopped from replicating.

Indications Urinary and respiratory tract infections.

Side Effects Nausea & vomiting, skin rashes, hypersensitivity

Other

Page 150: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Co-trimoxazole

Class Folate buggerer – sequential blockade. (actually trimethoprim and sulfamethoxazole)

MOA Trimethoprim blocks dihydrofolate reductase in bacteria, blocking cell replication. Sulfamethoxazole affects folate synthesis (earlier in same pathway). They potentiate one another, meaning that1/10th the dose is needed.

Indications Infections with pneumocystis carinii, which causes pneumonia in AIDS patients. Used in high doses.

Side Effects Combination of effects from trimethoprim and sulfamethoxazole.

Other

Page 151: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs which interfere with the

synthesis of Peptidoglycan

Page 152: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Penicillins

Class β-lactam antibiotics. Cell wall targetting

MOA Has a thiazolidine ring linked to a β-lactam ring. Prevents transpeptidisation. Antibiotic bonds to normal peptidoglycan which then can’t join with others to form a lattice. Bacterium open to osmotic pressures so lyses.

Indications Do not cross BBB.

Side Effects Hypersensitivity (antigenic), skin rashes and fever but can be anaphylactic shock. Can also interfere with gut flora causing GI disturbance.

Other Amidaze and β-lactamases can destroy the anti-biotic, normal defence mechanism. Using a β-lactamase inhibitor (clavulanic acid) normally gets round this problem. Other resistance stems from impermeability of the outer membrane, and modified penicillin binding sites.

Page 153: Jamie Manuell Year 2 Pharmacology & Therapeutics.

cefotaxime

Class Cephalosporin. Peptidoglycan targetting.

MOA Like penicillins targets the peptidoglycan synthesis. Can combine two or more synergistically which target different binding sites to ↑ efficiency.

Indications Meningitis due to G-ve intestinal bacteria

Side Effects Hypersensitivity as seen in penicillins. Nephrotoxicity, alcohol intolerance, diarrhoea.

Other Nearly all gram –ve bacteria possess β-lactamase, very effective against cephalosporins.

Page 154: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs which affect Bacterial Protein

Synthesis

Page 155: Jamie Manuell Year 2 Pharmacology & Therapeutics.

tetracyclin

Class Broad spectrum antibiotics

MOA Inhibit bacterial protein synthesis. Actively transported into bacteria where they interfere with protein synthesis. Competes with tRNA for the binding site, doesn’t kill, just stops growth.

Indications

Side Effects Form an insoluble complex with metal ions, so work best without food. GI disturbances common, because chelate calcium can stain teeth and lead to bone deformities. Some (doxycycline) produce sensitivity to sunlight.

Other Resistance based around tetracyclines being transported out of the cell, but also on alterations of the target, the bacterial ribosome.

Page 156: Jamie Manuell Year 2 Pharmacology & Therapeutics.

chloramphenicol

Class Broad spectrum ribosome binding.

MOA Inhibits protein synthesis by reversibly binding to the 50S subunit of the ribosome and inhibiting transpeptidation (formation of peptide bonds). Both bactericidal and bacteriostatic

Indications Broad spectrum. V. toxix so reserved for life threatening infections such as typhoid fever and meningitis.

Side Effects Depression of the bone marrow leading to pancytopenia. Not in babies because inadequate excretion can result in grey baby syndrome (40% mortality).

Other Not to pregnant women or neonates. Resistance due to choloramphenicol acetyl-transferase, plasmid mediated so resistance easily transferred

Page 157: Jamie Manuell Year 2 Pharmacology & Therapeutics.

gentamicin

Class Aminoglycosides

MOA Inhibit bacterial protein synthesis by binding to the 30S subunit of the ribosome, causing an alteration in codon:anticodon recognition. mRNA is read wrong, so faulty proteins produced. Transported in by O2 dependent active transport which chloramphenicol can block.

Indications Streptococcus lysteria or pseudomonas. Mostly gram-ve, some +ve. Polar so not absorbed – IV or IM. Not cross BBB. [Tissue] can become toxic.

Side Effects Ototoxicity – destruction of cells in the vestibular and cochlear regions. Damage to kidney tubules (so can’t be excreted – viscious circle)

Other Not good anaerobically. Enhanced by cell wall disrupting agents. Resistance due to conformational binding changes, failure of penetration, or inactivation by microbial enzymes.

Page 158: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anti-Mycobacterial Agents

Page 159: Jamie Manuell Year 2 Pharmacology & Therapeutics.

isoniazid

Class Antimycobacterial agent.

MOA Passes freely into mammalian cells and inhibits synthesis of mycolic acids, important constituents of the cell wall peculiar to mycobacteria.

Indications Mycobacterium (leprosy and tuberculosis). After phagocytosis, both can survive inside the macrophage.

Side Effects Rare skin eruptions, fever, GI disturbances.

Other

Page 160: Jamie Manuell Year 2 Pharmacology & Therapeutics.

rifampicin

Class Antimycobacterial agent

MOA Binds to and inhibits DNA-dependent RNA polymerase in prokaryotic but not eukaryotic cells. One of best anti-tuberculosis agents known. Active against most gram +ve and some gram-ve.

Indications Antimycobacterium, mostly tuberculosis.

Side Effects Rare side effects including skin eruptions, fever and GI disturbances.

Other

Page 161: Jamie Manuell Year 2 Pharmacology & Therapeutics.

pyrazinamide

Class Anti-mycobacterial. Related to nicotinamide

MOA Inactive at neutral pH but active in acidic pH. Effective once agent has been phagocytosed, as acidic in phagolysosomes. Involves metabolism of drug inside bacterium to produce a toxic product, pyrazinoic acid.

Indications Anti-mycobacterial (tuberculosis, leprosy

Side Effects Hepatotoxicity, and raised plasma urate levels can lead to arthralgia and gout.

Other Resistance can be rapid.

Page 162: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Antifungal Agents

Page 163: Jamie Manuell Year 2 Pharmacology & Therapeutics.

nystatin

Class Polyene macrolide

MOA Acts by forming a transmembrane ion channel in fungal cells, affecting permeability and transport functions. Not absorbed so used in GI tract or on skin. Affects fungi and some protozoa, mild mammalian effects, not at all to bacteria. Selective due to ergosterol rather than cholesterol in mammal membranes.

Indications skin or GI infections.

Side Effects Rare. Some GI disturbance in high dose, v. rare rash.

Other

Page 164: Jamie Manuell Year 2 Pharmacology & Therapeutics.

miconazole

Class Broad spectrum anti mycotic of the azole group.

MOA Azoles block the synthesis of ergosterol by interating with the enzyme needed to convert lanosterol to ergosterol. This alters the fluidity of the membrane which interferes with action of membrane associated enzymes. Also prevents the transformation of yeast cells into hyphae, the invasive and pathogenic form of the parasite.

Indications Orally for GI, IV for systemic fungal infections

Side Effects Rare, some GI disturbance, also pruritus, blood dyscrasias.

Other

Page 165: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anti-Viral Agents

Page 166: Jamie Manuell Year 2 Pharmacology & Therapeutics.

acyclovir

Class Nucleic acid synthesis inhibitor. A guanosine derivative.

MOA Acyclovir is converted to the monophosphate form by thymidine kinase – the virus’s own kinase is more effective at converting it than the host cell’s own kinase, and then converted to the active triphosphate. Therefore it is only activated in infected cells. It is used as a guanine substitute, which prevents DNA synthesis.

Indications Herpes simplex virus

Side Effects Minimal. Local inflammation around injection site if extravasion occurs (alkaline solution so irritant). Renal dysfunction reported. Nausea and headache.

Other Resistance due to changes in viral genes coding for thymidine kinase or DNA polymerase, and acyclovir resistant form have caused pneumonia and encephalitis in immunocompromised patients.

Page 167: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Zidovudine (AZT)

Class Analogue of thymidine, reverse transcriptase inhibitor.

MOA Active inhibitor of reverse transcriptase. Phosphorylated to the triphosphate form, where it competes with cellular triphosphates, essential for formation of proviral DNA by viral reverse transcriptase (viral RNA dependent DNA polymerase). It is incorporated into the growing DNA strand which results in chain termination.

Indications In retroviruses such as HIV virus. Reduces risk of transmission from mothers, reduces chance of opportunistic infection, HIV associated dementia etc.

Side Effects Anaemia and neutropenia, abnormalities of liver function and myopathy, GI disturbances, confusion, anxiety, depression, rash.

Other Mammal α-DNA polymerase is resistant but mitochondrial γ-DNA polymerase is susceptible. Resistance is due to changing a.a. in the viral reverse transcriptase, so it is a constantly moving target.. Also ↓ phosphoylation of zidovudine to its active form, ↑ in viral load, and increased virulence of the pathogen.

Page 168: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anxiolytics

Page 169: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Diazepam

Class Benzodiazepine (long acting, 32hrs)

MOA Benzodiazepines potentiate the action of GABA by binding to a site on GABAA receptors, increasing their affinity for GABA. This results in an increased opening fluctuations of these ligand gated Cl- channels, thus increasing the inhibitory effects on postsynaptic firing.

Indications Short term relief of severe anxiety and severe insomnia, preoperative sedation, status epilepticus, and acute alcohol withdrawl.

Side Effects Drowsiness, ataxia, reduced psychomotor performance, dependence after 4-6 weeks. If taken in combination with alcohol, fatal respiratory depression can result. OD treated with flumazenil

Other Not be given to people with bronchopulmonary disease, and have combination effects with other depressants such as alcohol, barbiturates, and antihistamines.

Page 170: Jamie Manuell Year 2 Pharmacology & Therapeutics.

oxazepam

Class Benzodiazepine (short acting, 8hrs)

MOA Acts to potentiate effects of GABA, by binding to GABAA receptors and increasing their affinity for GABA, therefore increasing the frequency with which Cl- is allowed into the cell and ↑ the inhibitory effect on the postsynaptic cell.

Indications Short term relief of severe anxiety and insomnia, preop sedation, statuss epilepticus, and acute alcohol withdrawl.

Side Effects Drowsiness, ataxia, and ↓ psychomotor performance are seen. Dependence develops after 4-6 weeks, fatal respiratory depression if taken in combination with alcohol (or other CNS depressants)

Other

Page 171: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Buspirone

Class Anxiolytic, Azapirones, act on 5-HT (serotonergic) receptors

MOA In the raphe nucleus, dendrites of the serotonergic neurones have autoreceptors (5-HT1A)which ↓ the firing of 5-HT neurons. Azapirones act as partial agonists at these receptors.

Indications Short term relief of general anxiety disorder.

Side Effects Nervousness, dizziness, headache and light headedness. Does not cause sedation or cognitive impairment, doesn’t potentiate alcohol, and only has a minimal risk of dependence.

Other Not in epileptics. Effects evolve over 1-3 weeks.

Page 172: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Sedatives / Hypnotics

Page 173: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Temazepam

Class Short lasting benzodiazepine

MOA Potentiates the effects of GABA by binding to a site on GABAA receptors, ↑ their affinity for GABA, ↑ amount of Cl- entering the cell and so inhibiting the firing of the neurone.

Indications Given in short term relief of severe anxiety and insomnia, preop sedation, status epilepticus, and acute alcohol withdrawl.

Side Effects Drowsiness, ataxia, and ↓ psychomotor performance are seen. Dependence develops after 4-6 weeks, fatal respiratory depression if taken in combination with alcohol (or other CNS depressants)

Other

Page 174: Jamie Manuell Year 2 Pharmacology & Therapeutics.

amobarbital

Class barbiturates

MOA These prolong the time Cl- channels are opened at GABA receptors whereas benzodiazepines ↑ the firing frequency.

Indications Sedation, reduction of anxiety. Not used now

Side Effects More depressant than benzodiazepines as they ↑ Cl- conductance directly, decreasing the neurones sensitivity to excitatory transmitters.

Other

Page 175: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Chloral hydrate

Class Hypnotic

MOA Chloral hydrate is metabolised to trichloroethanol, which I an effective hypnotic. Cheap but no advantage over newer benzodiazepines.

Indications Previously popular hypnotic for children, but worse than benzodiazepines and children shoudn’t be sedated anyway.

Side Effects Gastric irritation

Other

Page 176: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anticonvulsants

Page 177: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Phenytoin

Class Sodium channel inhibitors, anti epileptic / arrhythmic.

MOA Bind preferentially to the closed Na+

channels, preventing them from opening, and so preventing depolarisation. In a seizure, the number of channels susceptible to blockade is higher, meaning that normal transmission is relatively unaffected.

Indications Seizures, except absence seizures

Side Effects Dosage effects: Affect cerebellovestibular system, leading to ataxia, blurred vision, and hyperactivity. Acute toxicity leads to sedation and confusion. Non dosage effects: collagen effects such as gum hypertrophy, coarsening of facial features, allergic reactions (rash, hepatitis, lymphadenopathy), haematological effects (megaloblastic anaemia), hirsutism, teratogenic effects (congenital malformations)

Other This drug is liver saturable – will build up in system until effects become marked suddenly, like beer. Fosphenytoin is a water soluble pro-drug.

Page 178: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Carbamazepine

Class Na+ channel blockers

MOA Inhibits fast Na+ channels involved in neuronal excitation. Prevents excessive depolarisation

Indications Seizure suppression

Side Effects Limited to NS – ataxia, nystagmus, dysarthia, vertigo, and sedation.

Other

Page 179: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Sodium valproate

Class anticonvulsant

MOA Like phenytoin causes use dependent block of voltage gated Na+ channels. Also Inhibit GABA metabolism by GABA transaminase

Indications All forms of epilepsy

Side Effects GI upset, liver failure.

Other Hepatic toxicity exacerbated when used with other anti-convulsants. First line for many types of seizure syndromes.

Page 180: Jamie Manuell Year 2 Pharmacology & Therapeutics.

vigbatrin

Class Anti convulsant

MOA Inhibit GABA metabolism by irreversible inhibition of GABA transaminase.

Indications Tough epilepsy

Side Effects Drowsiness, dizziness, depression, and visual hallucinations

Other Side effect of hallucinations, so not in people with history of psychosis. New drug used in conjunction with other therapies.

Page 181: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Lamotrigine

Class Anti epileptic

MOA Acts by effect on sodium channels, and inhibiting release of excitatory amino acids.

Indications Monotherapy and treatment of partial and generalised tonic clonic seizures. Neuralgic pain (nerve root pain) (by stabilising neurones involved, limiting activation)

Side Effects Rashes, fever, malaise, drowsiness, hepatic dysfunction

Other Not in hepatic impairment

Page 182: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anaesthetics

Page 183: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Local Anaesthetics

Page 184: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Cocaine(Ester)

Class Local anaesthetic

MOA Blocks Na+ channels. Also prevents the uptake of NA at the synapse.

Indications Ear, nose and throat surgeons

Side Effects Does not cause CNS depression like the other local anaesthetics because it causes euphoria through long lasting chatecolamine action.

Other

Page 185: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Procaine

Class Local anaestheic.

MOA Basically a synthetic derivative of cocaine. Causes sodium channel block

Indications Seldom used because of its CNS side effects

Side Effects Causes CNS depression the worst out of all the local anaesthetics. Resp depression, myocardial depression and vasodilation, visual disturbances and twitching.

Other

Page 186: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Lidocaine(lignocaine)

Class Local anaestheticAmide

MOA

Indications Widely used in all applications, EMLA

Side Effects Caused by leaking into the circultion. Restlessness, tremor, confusion, agitation, CNS depression.

Other

Page 187: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Bupivicaine

Class Local anaesthetic

MOA Slow onset, long lasting local anaesthetic, with moderate tissue penetration.

Indications Epidural and spinal anaesthesia

Side Effects Systemic problems as with the others.

Other

Page 188: Jamie Manuell Year 2 Pharmacology & Therapeutics.

General Anaesthetics

Page 189: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Nitrous Oxide

Class Inhalational GA

MOA Blockade of NMDA type Glutamate receptors

Indications Rapid control of depth of anaesthesia

Side Effects

Other

Page 190: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Halothane& Enflurane

Class Inhalational GA

MOA Potentiate GABAa receptor (and Glycine receptors in the spinal cord to educe reflexes), inhibition of nicotinic Ach receptors & facilitate TREK (backround leak of Potassium due to channel opening leading to reduced neuronal activity)

Indications

Side Effects

Other

Page 191: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Propofol & Etomidate

Class IV GA

MOA Potetiates the action of GABAa receptors, most effective when Beta subunits of the GABAa receptor complex predominate, anaesthesia from depression of Thalamocortical neurones and influence on the reticular activating system, amnesia from depression of the synaptic transmission at the Hippocampus and Amygdala

Indications

Side Effects

Other

Page 192: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Usual GA Cocktails

• Loss of Consciousness (Induction by IV GA – Propofol)

• Supression of Reflexes (Maintainance with Enflurane)

• Analgesia (Fentanyl)• Muscle Relaxation (Suxamethonium)• Amnesia (Midazolam – BDZ)

Page 193: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Anti-Parkinsonian Drugs

Page 194: Jamie Manuell Year 2 Pharmacology & Therapeutics.

L-dopa

Class Exogenous precursor to Dopamine

MOA Allows the remaining (30% or lower) DA-ergic neurones to function by having more of a reservoir of DA to use

Indications Treats rigidity & tremor

Start with low dose of the drug and increase dose until maximum benefit without side effects

Effectiveness of L-DOPA declines with time!

Side Effects

Acute (N&V, Hypotension and a Schizophrenic like syndrome)

Chronic (Dyskinesias and On/Off fluctuations)

Other To prevent N&V formulations of L-DOPA have been created with a peripheral DOPA decarboxylase inhibitorSinamet (+ Carbidopa)Madopar (+Benserazide)

Page 195: Jamie Manuell Year 2 Pharmacology & Therapeutics.

bromocriptine

Class DA2 receptor agonist.

MOA Simple Agonist, no need of functioning DA-ergic neurones as in L-DOPA therapy

Indications Acromegaly,, Benign breast tumour relief, Acromegaly, Parkinson’s, prolactinoma

Side Effects Nausea, vomiting, ab cramps, psychomotor excitation, dyskinesias, postural hypotension, vasospasm in fingers and toes

Other Caution in Raynauds disease where vasospasm in fingers and toes happens already.

Page 196: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Deprenyl (Selegiline)

Class Selective for MAO-B, predominates in dopaminergic areas of CNS. Actions are without peripheral side effects of none-selective MAO-I’s

MOA Increases available DA

Indications Can be given alone in the early stages of the disease.

Or in combination with L-DOPA, reduce the dose of L-DOPA by 30-50%

Side Effects Side effects are rare - hypotension, nausea/vomiting, confusion and agitation.

Other

Page 197: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Entacapone

Class Peripheral and CNS COMT inhibitor

MOA CNS - Prevents breakdown of dopamine in the brain

Peripheral - COMT in the periphery converts L-DOPA to 3-0-methyl-DOPA (3-0MD). 3-OMD and L-DOPA compete for same transport system into the brain. COMT inhibitors stop 3-OMD formation thus increasing the bioavailability of L-DOPA, Thus more L-DOPA converted to dopamine in the CNS. Reduce L-DOPA dosage!

Indications

Side Effects

Other

Page 198: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Neuroleptic Drugs

Page 199: Jamie Manuell Year 2 Pharmacology & Therapeutics.

chlorpromazine

Class Typical antipsychotic

MOA CNS Antagonist against D2, Ach and H

Indications Acute and Chronic Psychoses, Schizophrenia and the manic phase in Bipolar disorder

Side Effects Less incidence of extra pyramidal disorders in contrast to the more potent neuroleptics (Haloperidol) most SE from the drugs Anti Ach activity (sedation, dry mouth, constipation, urinary retention)

Other

Page 200: Jamie Manuell Year 2 Pharmacology & Therapeutics.

haloperidol

Class Typical antipsychotic

MOA CNS Strong Antagonist against D2 (and to a lesser extent Ach & H)

Indications Schizophrenia

Side Effects

Extrapyramidal symptoms like acute dyskinesias (Too much Ach), Tardive Dyskinesia (Upregulation of DA receptors), Parkinsonian like syndrome and possible increase in Prolactin levels

Other Can be used as an anti emetic

Page 201: Jamie Manuell Year 2 Pharmacology & Therapeutics.

sulpiride

Class Selective CNS D2 receptor Antagonist

MOA Simple antagonist

Indications Schizophrenia

Side Effects

Extrapyramidal symptoms like acute dyskinesias (Too much Ach), Tardive Dyskinesia (Upregulation of DA receptors), Parkinsonian like syndrome and definite increase in Prolactin levels (Breast Cancer?)

Other

Page 202: Jamie Manuell Year 2 Pharmacology & Therapeutics.

clozapine

Class Atypical antipsychotic

MOA CNS Antagonist against D2, Ach, H & 5HT (Hence Atypical)

Indications Schizophrenia

Side Effects

Agranulocytosis and myocarditis it may rarely lower seizure threshold, cause leukopenia, cause hepatic dysfunction, weight gain and be associated with type II diabetes. More common side effects are predominantly anticholinergic in nature, with dry mouth, sedation and constipation

Other

Page 203: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Cytotoxic Drugs

Page 204: Jamie Manuell Year 2 Pharmacology & Therapeutics.

cyclophosphamide

Class Alkylating agent

MOA Highly reactive molecules that bind irreversibly to cell macromolecules causing intra and inter chain cross links (Notably DNA / RNA) binding sites N7 of G, N1 & N3 of A and N3 of C

Indications Chemotherapy (& immunosupression at lower doses)

Side Effects

General toxic side effectsMyelosupressionImpaired wound healingDepression of GrowthSterilityTeratogenicityLoss of HairN&V

Other

Page 205: Jamie Manuell Year 2 Pharmacology & Therapeutics.

methotrexate

Class Antimetabolite

MOA Folate antagonist and so reduces the synthesis of Purine nucleotides (Reduction of the enzyme DHFR)

Indications Chemotherapy (& immunosupression at lower doses)

Side Effects

General toxic side effectsMyelosupressionImpaired wound healingDepression of GrowthSterilityTeratogenicityLoss of HairN&V

Other

Page 206: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Azathioprine

Class Antimetabolite

MOA Purine analogue, inhibit Purine synthesis and is incorperated into DNA itself

Indications Chemotherapy (& immunosupression at lower doses)

Side Effects

General toxic side effectsMyelosupressionImpaired wound healingDepression of GrowthSterilityTeratogenicityLoss of HairN&V

Other

Page 207: Jamie Manuell Year 2 Pharmacology & Therapeutics.

bleomycin

Class Cytotoxic Antibiotic

MOA Causes fragmentation of DNA chains and can act on non dividing cells. Bleomycin is a metal chelating glycopeptide antibiotic which uses Iron ions to create ROS which then cause DNA damage

Indications Chemotherapy

Side Effects

General toxic side effectsMyelosupressionImpaired wound healingDepression of GrowthSterilityTeratogenicityLoss of HairN&V

Other

Page 208: Jamie Manuell Year 2 Pharmacology & Therapeutics.

doxorubicin

Class Cytotoxic Antibiotic

MOA Topoisomerase II inhibitor and in such creates DNA strand breaks

Indications Chemotherapy

Side Effects

General toxic side effectsMyelosupressionImpaired wound healingDepression of GrowthSterilityTeratogenicityLoss of HairN&V

Other

Page 209: Jamie Manuell Year 2 Pharmacology & Therapeutics.

vincristine

Class Vinca Alkaloid

MOA Spindle Poisons and exert there actions by binding to tubulin causing depolymerisation of microtubules and therefore producing metaphase arrest

Indications Chemothrapy

Side Effects

General toxic side effectsMyelosupressionImpaired wound healingDepression of GrowthSterilityTeratogenicityLoss of HairN&V

Other

Page 210: Jamie Manuell Year 2 Pharmacology & Therapeutics.

etoposide

Class Podophyllotoxin

MOA Topoisomerase II inhibitor, prevents DNA replication and causes strand breaks

Indications Chemotherapy

Side Effects

General toxic side effectsMyelosupressionImpaired wound healingDepression of GrowthSterilityTeratogenicityLoss of HairN&V

Other

Page 211: Jamie Manuell Year 2 Pharmacology & Therapeutics.

procarbazine

Class Miscellaneous anticancer drug(MAO-I)

MOA Inhibition of incorporation of Thymidine and adenine into DNA

Indications Chemotherapy

Side Effects

General toxic side effectsMyelosupressionImpaired wound healingDepression of GrowthSterilityTeratogenicityLoss of HairN&V

Other

Page 212: Jamie Manuell Year 2 Pharmacology & Therapeutics.

cisplatin

Class Miscellaneous anticancer drug(Platinum Compound)

MOA After dissociation of a Cl- from the drug this generates a reactive complex that cross links between G units in DNA (Similar to alkylating agents)

Indications Chemotherapy

Side Effects

General toxic side effectsMyelosupressionImpaired wound healingDepression of GrowthSterilityTeratogenicityLoss of HairN&V (WORST SIDE EFFECT!)

Other

Page 213: Jamie Manuell Year 2 Pharmacology & Therapeutics.

goserelin

Class GnRH agonists.

MOA Blocks oestrogen production, constant bombardment of the adenohypophesis with the GnRH agonist causes down regulation of the GnRH receptors

Indications Breast cancer in pre menopausal women.

Side Effects

Other Can also block oestrogen actions using enzymatic inhibition, or just inhibit the actions of oestrogen within the tumour cell.

Page 214: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Drugs for Endocrine Disorders

Page 215: Jamie Manuell Year 2 Pharmacology & Therapeutics.

tamoxifen

Class Estradiol analogue – anti-oestrogen

MOA Works by acting as a competitive inhibitor at the ER on the breast cell tumours. This stops the effect and holds the cell at the G1 phase.

Indications Endocrine treatment of choice for postmenopausal women

Side Effects

Other

Page 216: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Ferrous sulphate

Class Oral iron compound

MOA Ingested and solves iron deficiency

Indications Iron deficiency anaemia

Side Effects none

Other

Page 217: Jamie Manuell Year 2 Pharmacology & Therapeutics.

cabergoline

Class DA2 receptor agonist with some DA1 actions.

MOA

Indications Hyperprolactinaemia. Not as good as bromocriptine but side effects are less pronounced and it is longer lasting.

Side Effects

Other Mutual antagonists with anti-psychotics. Sympathomimetic toxicity is increased. Exacerbates effects of alcohol.

Page 218: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Octreotide

Class Somatostatin analogue

MOA Imitates actions of somatostatin by inhibiting production of Growth hormone.

Indications Acromegaly – short term treatment before pituitary surgery.

Side Effects

Other

Page 219: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Ethinyloestradiol& medroxyprogesterone

Class TSH & LH replacement therapy

MOA Replaces actions of progesterone and oestrogen.

Indications Hormone replacement in cases where gonadotrophins are no longer produced in pan hypopituitarism

Side Effects

Other

Page 220: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Terlipressin

Class V1 receptor agonist.

MOA Acts at V1 receptors as an agonist casuing an increase in IP3/DAG and so causing vasoconstriction, platelet aggregation, hepatic glycogenolysis, ↑ vWF and Factor VIII, ↑ ACTH and so cortisol.

Indications Stopping bleeding from oesophageal varices, prolongs the actions of local anaesthetics.

Side Effects

Other

Page 221: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Desmopressin

Class V2 receptor agonist

MOA Imitates actions of vasopressin in the distal collecting duct as an anti diuretic

Indications Given in central diabetes insipidus. Has no effect with nephrogenic diabetes. Thiazides used for nephrogenic diabetes insipidus.

Side Effects

Other

Page 222: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Lithium &dimethylchlorotetracycli

ne

Class Inhibitors of vasopressin action on the distal tubule

MOA Prevents anti-diuretic actions of excessive vasopressin

Indications Excessive vasopressin production.

Side Effects

Other

Page 223: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Levothyroxine

Class Thyroxine analogue

MOA Acts to raise metabolism in tissues – replacing T4

Indications hypothyroidism

Side Effects

Other

Page 224: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Liothyronine

Class T3 analogue – tri-iodothyronine

MOA Replacement of T3. binds to intracellular receptor where I tis transported to the DNA and causes transcription of tissue specific DNA regulated effects, ie raising BMR, sesnsitising tissue to sympathetic stimuli etc.

Indications Hypothyroidism. At birth to prevent cretinism

Side Effects

Other

Page 225: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Protirelin

Class Thyrotrophin releasing hormone analogue

MOA Stimulates release of thyroxine from the thyroid gland

Indications Used in stimulation tests of the thyroid to test function.

Side Effects

Other

Page 226: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Metformin

Class Insulin sensitiser (Biguanide)

MOA Requires endogenous insulin production. Works by decreasing glucose output by the liver and increasing its uptake by liver and peripheral cells.

Indications Type 2 Diabetes mellitus in fat people whose diet control hasn’t worked properly

Side Effects Lactic acidosis, ↓ vitamin B12 absorption. Nausea and vomiting, headache, anorexia.

Other Not in renal insufficiency or hepatic impairment.

Page 227: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Glibenclamide

Class Sulphonurea

MOA These block ATP dependent potassium channels in the membranes of the pancreatic β cells, causing depolarisation, calcium influx, and insulin release.

Indications Type II Diabetes Mellitus where there is still β cell activity in the pancreas

Side Effects Potential hypoglycaemia in people with renal or hepatic insufficiency.

Other Contraindications in people with ketoacidosis

Page 228: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Rosiglitazone

Class Thiazolidinediones. Insulin sensitisers

MOA Work by reducing peripheral insulin resistance, leading to a reduction in plasma glucose

Indications Uncontrolled Type II DM

Side Effects Weight Gain, potential liver failure.

Other Must only be used in combination with a sulphonylarea or metformin.

Page 229: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Acarbose

Class α glucosidase inhibitor

MOA Inibits the breakdown of oligosaccharides (starch and sucrose), therefore delays CHO absorption. This reduces the –CHO peaks a bit like metformin.

Indications Useful in the obese diabetic patient.

Side Effects GI gas

Other Not in pregnancy, breastfeeding, bowel problems.

Page 230: Jamie Manuell Year 2 Pharmacology & Therapeutics.

carbimazole

Class Thiourylenes – also includes propylthiouracil

MOA Blocks thyroperoxidase which is responsible for the production of thyroglobulin and T3 & T4 synthesis. May also ↓ antibody production in Grave’s disease and ↓ the conversion of T4 to T3 in peripheral tissues.

Indications Hyperthyroidism

Side Effects Hypothyroidism

Other

Page 231: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Iodide

Class Anion inhibitor

MOA Inhibit the conversion of T4 to T3, of organification and of hormone secretion. They also reduce the size and vascularity of the gland

Indications Hyperthyroidism

Side Effects Allergic responses

Other

Page 232: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Radioiodine

Class Anti hyperthyroid

MOA Selectively taken up by the thyroid gland where it has very local cytotoxic effects due to β particles. The γ particles pass straight out. Can destroy the over producing thyroid follicular cells.

Indications Low dose test of thyroid function, high dose, hyperthyroidism or thyroid tumours.

Side Effects Not in children or pregnancy

Other

Page 233: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Miscellaneous Drug

Information

Page 234: Jamie Manuell Year 2 Pharmacology & Therapeutics.

SYMPathetic

α1located postsynaptically, Their activation causes SM contraction (except in non sphincter GI), glycogenolysis in the liver, and potassium release from the liver & salivary glands. G-protein linked, & by increase in 2nd messengers.

α2Located most pre, but post on hepatocytes, platelets and BV SM. Activation of pre inhibits NA release and provides end product negative feedback. Activation of post causes BV constriction & platelet aggregation. G-protein linked & by decrease in 2nd messengers.

β1Mostly postsynaptic in the heart, platelets and non sphincter GI. Activation causes rise in rate and force of contraction of the heart, relaxation of GI, platelet aggregation, rise in NA, lipolysis in Fat, amylase secretion from salivary glands.

G-protein and rise in 2nd messenger cAMP.

β2Located post, SM relaxation, glycogenolysis in liver, inhibition of histamine from mast cells, tremor in skeletal muscle. G-protein and and increase in cAMP.

Page 235: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Parasympathetic

M1Neuroparietal normally found in the CNS, peripheral neurons, and gastric parietal cells. Effects are excitatory, depolarizing membranes through a decrease in K conductance. Activation causes central excitation and gastric acid secretion, transduction through G-proteins and Increase in 2nd messengers.

M2Neurocardiac are found in the heart and on peripheral neurons. Effects are inhibitory raising K conductance(<rate), and inhibiting calcium channels(<force). G-protein transduction with decrease of 2nd messengers.

M3Smooth muscle-glandular found in obvious. Excitatory by increasing Na conductance. Causes SM contraction and secretions such as saliva and sweat. G-proteins and increase in 2nd messengers. Also on vascular epitelium, activation of which causes EDRF (NO).

M4Eye. Causes constriction of the pupil and accomodation for near vision. Transduction is via G-proteins and a decrease in 2nd messenger.

Page 236: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Multiple drug therapies

Helicobacter pylori

Metronidazole/amoxycillin, clarithromycin, Omeprazole

Tuberculosis 1st phase of 2 months: isoniazid, rifampicin, pyrazinamide (+ethambutol if resistant)

2nd phase of 4 months:

Isoniazid and rifampicin

Page 237: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Histamine

H1 Histamine in hypersensitivity reaction.

•Capillary and venous dilation (systemic hypotension

•↑ vascular permeability (oedema)

•Contraction of SM (bronchial and GI contraction)

•↑ mucus secretion by goblet cells

H2 Regulation of gastric acid secretion.

-H2 receptors respond to histamine secreted from enterochromaffin like cells that are adjacent to the parietal cells.

-Negative feedback if on mast cells and basophils.

-Increases vasopermeability & dilation and stimulates exocrine glands.

H3 Neurotransmission. Not sure what. Possible presynaptic inhibition of NT release in the CNS and autonomic NS? Role in pain perception?

Page 238: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Vasopressin Receptors

V1 Vascular smooth muscle (prevention of blood loss from oesophageal varices), non vascular smooth muscle, anterior pituitary, Liver, platelets (Stimulation of factor VIII and von Willbrandt factor), Brain and CNS

V2 Kidney (distal collecting duct), CNS

Page 239: Jamie Manuell Year 2 Pharmacology & Therapeutics.

Glucocorticoid SE

osteoporosis ↑ osteoclast activity, ↓ osteoblast activity

Gastric ulceration ↓ PG production in stomach (lipocortin ↓ arachidonic acid.)

Suppression of HPA -ve feedback on pit. & hypothalamus

hypertension Na+ Cl-, water retention; ↑ adrenoceptors hence ↑ response.

infection Immunosupression

Skin thinning ↓ connective tissue, ↓ tissue turnover and repair

Muscle wasting & buffalo hump

↓ storage of glucose in muscle, leads to an ↑ in fat deposition.

Cataracts & glaucoma